MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ibd/izag001

Медицинская библиотека · Inflammatory bowel diseases · 2026

Advanced therapies for inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and meta-analysis.

Li Darrick K, Chaar Abdelkader, Arabi Tarek, Quraishi Mohammed Nabil, Elgamal Mohamed, Alahdab Fares, Grimshaw Alyssa A, Al-Bawardy Badr

Систематический обзорСтатьяМетаанализПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Up to 70%-80% of patients with primary sclerosing cholangitis (PSC) will have concomitant inflammatory bowel disease (IBD). Scarce data are available regarding outcomes of advanced therapies to treat IBD-PSC. We performed a systematic review and meta-analysis to assess the effectiveness and safety of advanced therapies in IBD-PSC.

METHODS

A systematic search was conducted in Cochrane Library, Embase, Google Scholar, Ovid Medline, PubMed, Scopus, and Web of Science from database inception to January 29, 2025. We included studies that reported on IBD clinical response with advanced therapies. Meta-analysis was performed using the random effects model. Subgroup analyses were conducted to further investigate proportion differences between covariates.

RESULTS

Nineteen studies (n = 864) were included in the final analysis. Among IBD-PSC patients treated with advanced therapies, clinical response was observed in 52% (95% CI, 40%-65%; I2 = 85%), clinical remission in 43% (95% CI, 25%-62%; I2 = 91%), and endoscopic remission in 26% (95% CI, 13%-42%; I2 = 75%). Infections occurred in 22% of patients (95% CI, 8%-40%; I2 = 82%) and acute cholangitis was observed in 14% of patients (95% CI, 2%-33%; I2 = 80%). The endoscopic remission rate with anti-tumor necrosis factor (anti-TNF) agents was 29% (95% CI, 10%-52%; I2 = 28%) vs. 15% (95% CI, 4%-29%; I2 = 70%) in those who received non-anti-TNF biologics. The rates of overall infections were similar in patients who received anti-TNF vs. non-anti-TNF biologics.

CONCLUSIONS

Advanced therapies show efficacy and comparable safety in IBD-PSC. The study findings are limited by significant heterogeneity and further prospective studies with standardized endpoints are needed.

Для цитирования: Li Darrick K, Chaar Abdelkader, Arabi Tarek, Quraishi Mohammed Nabil, Elgamal Mohamed, Alahdab Fares, Grimshaw Alyssa A, Al-Bawardy Badr. Advanced therapies for inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and meta-analysis.. Inflammatory bowel diseases. 2026. DOI: 10.1093/ibd/izag001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.